Bertilimumab is a first-in-class human monoclonal antibody that targets and lowers eotaxin-1 levels. Eotaxin-1 is a chemokine that attracts eosiniphils to sites of inflamation - thus by blocking eotaxin-1, bertilimumab may reduce eosinophile migration or activation and thus provide a benefit to patients suffering from a variety of immunologic and inflammatory diseases. To date, bertilimumab has been well tolerated, with over 100 subjects having received bertilimumab in clinical trials, and has shown promising signs of activity in patients with moderate-to-severe bullous pemphigoid, a rare skin blistering disease. Read More 

Latest News

PRESS RELEASE October 18, 2017

Immune Pharmaceuticals Announces Presentation at The Liver Meeting 2017 | Read more 


PRESS RELEASE September 27, 2017

Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid | Read more 


PRESS RELEASE August 29, 2017

Immune Pharmaceuticals Receives NASDAQ Letter | Read more 


See All News 

Upcoming Events

No upcoming events found

See All Events